Eagle Pharmaceuticals Inc (EGRX)

Precedente Chiudi:

$4.24

Aprire:

$4.25

Volume 24 ore:

79,461

Capitalizzazione di mercato:

$53.91M

Reddito:

$257.55M

Utile/perdita netta:

$11.95M

Rapporto P/E:

4.5714

EPS:

0.91

Flusso di cassa netto:

$-9.39M

1 W Prestazione:

-9.76%

1M Prestazione:

-17.46%

6M Prestazione:

-69.52%

1 anno Prestazione:

-84.98%

Intervallo 1D:

$4.05

$4.25

Portata 52W:

$4.05

$30.40

Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile

Nome

Eagle Pharmaceuticals Inc

Settore

Healthcare (1191)

Industria

Drug Manufacturers - Specialty & Generic (4)

Telefono

201-326-5300

Indirizzo

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ

Dipendente

108

Cinguettio

@eaglepharm

Prossima data di guadagno

2024-05-07

Ultimi documenti SEC

EGRX's Discussions on Twitter

Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2018-11-01	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2018-10-31	Downgrade	Piper Jaffray	Overweight → Neutral
2018-03-21	Reiterato	Mizuho	Underperform
2017-11-09	Reiterato	RBC Capital Mkts	Outperform
2017-09-06	Reiterato	Mizuho	Underperform
2017-07-27	Reiterato	Mizuho	Underperform
2017-07-27	Reiterato	RBC Capital Mkts	Outperform
2017-05-09	Reiterato	RBC Capital Mkts	Outperform
2017-01-09	Downgrade	Mizuho	Neutral → Underperform
2016-11-16	Downgrade	Mizuho	Buy → Neutral
2016-11-03	Aggiornamento	Mizuho	Neutral → Buy
2016-11-03	Reiterato	RBC Capital Mkts	Outperform
2016-10-26	Reiterato	Mizuho	Buy
2016-08-16	Reiterato	Mizuho	Neutral
2016-06-20	Downgrade	Mizuho	Buy → Neutral
2016-05-10	Reiterato	RBC Capital Mkts	Outperform
2016-03-18	Reiterato	Mizuho	Buy
2016-02-26	Reiterato	Mizuho	Buy
2015-12-09	Iniziato	Mizuho	Buy
2015-07-29	Reiterato	Piper Jaffray	Overweight

Mostra tutto

Eagle Pharmaceuticals Inc Borsa (EGRX) Ultime notizie

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

GlobeNewswire Inc.

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

GlobeNewswire Inc.

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

GlobeNewswire Inc.

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

GlobeNewswire Inc.

Eagle Pharmaceuticals Announces Management Change

GlobeNewswire Inc.

Eagle Pharmaceuticals Inc Azioni (EGRX) Dati Finanziari

Eagle Pharmaceuticals Inc (EGRX) Reddito 2024

Eagle Pharmaceuticals Inc (EGRX) Reddito netto 2024

Eagle Pharmaceuticals Inc (EGRX) Flusso di cassa 2024

Eagle Pharmaceuticals Inc (EGRX) Utile per azione 2024

Eagle Pharmaceuticals Inc Azioni (EGRX) insider trading